Fluoropyrimidines (FPs) are antineoplastic drugs widely used in the treatment of various solid tumors. Nearly 30% of patients treated with FP chemotherapy experience severe FP-related toxicity, and in some cases, toxicity can be fatal. Patients with reduced activity of DPD, the main enzyme responsible for the breakdown of FP, are at an increased risk of experiencing severe FP-related toxicity. While European regulatory agencies and clinical societies recommend pre-treatment DPD deficiency screening for patients starting treatment with FPs, this is not the case with American ones. Pharmacogenomic guidelines issued by several pharmacogenetic organizations worldwide recommend testing four DPD gene () risk variants, but these can predict only a proportion of toxicity cases. New evidence on additional common polymorphisms, as well as identification and functional characterization of rare variants, could partially address the missing heritability of DPD deficiency and FP-related toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2022-0135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.
Clin Transl Sci
December 2024
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
PACIFIC-PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of DPYD/UGT1A1 genotype-guided dosing on severe fluoropyrimidine (FP) and irinotecan-related toxicities and hospitalizations, compared to historical controls. This prospective single arm trial enrolled patients starting FP/irinotecan for any cancer between 7 January 2021 and 25 February 2022 from four Australian hospitals (one metropolitan, three regional). During the accrual period, 462/487 (95%) consecutive patients screened for eligibility for DPYD and 50/109 (46%) for UGT1A1 were enrolled and genotyped (feasibility analysis), with 276/462 (60%) for DPYD and 30/50 (60%) for UGT1A1 received FP/irinotecan (safety analysis).
View Article and Find Full Text PDFNovel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study.
Pharmaceutics
July 2024
Instituto de Investigación Biosanitaria de Granada (Ibs.Granada), 18012 Granada, Spain.
Fluoropyrimidines (FPs) are commonly prescribed in many cancer streams. The EMA and FDA-approved drug labels for FPs recommend genotyping the *2A (rs3918290), *13 (rs55886062), *HapB3 (rs56038477), alleles, and rs67376798 before treatment starts. We implemented the genotyping in our daily clinical routine, but we still found patients showing severe adverse drug events (ADEs) to FPs.
View Article and Find Full Text PDFEvaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia.
Intern Med J
September 2024
University of Newcastle, College of Health, Medicine and Wellbeing, School of Medicine and Public Health, Newcastle, New South Wales, Australia.
Background: Despite common global usage, fluoropyrimidine (FP; 5-flurouracil and capecitabine)-related chemotherapy toxicity is poorly reported in the literature, with serious toxicity ranging from 10% to 40% and early toxicity (within 60 days of exposure) quoted at 14%. Data reflecting the incidence of Grades 3-5 FP-related toxicity in Australian cancer patients is scant, despite the significant impact of toxicity on patients (hospitalisations, intensive care unit (ICU) admissions and even death).
Aims: This retrospective audit evaluated Grades 3-5 toxicities in a contemporaneous cohort of 500 patients receiving FP chemotherapies within the Hunter-New England Local Health District from June 2020 to June 2022.
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
Br J Cancer
March 2024
Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France.
Article Synopsis
- - Dihydropyrimidine dehydrogenase (DPD) deficiency is a major cause of severe toxic reactions in patients treated with fluoropyrimidine (FP) drugs; a meta-analysis was done to evaluate the effect of specific DPYD gene variants and other clinical factors on predicting severe toxicity.
- - The study focused on Caucasian patients not receiving FP dose adjustments due to DPD deficiency, finding that the prevalence of severe toxicity (G4-5) after 12 weeks was 7.3%, with certain genetic variants notably increasing risk.
- - Significant findings indicate that combining DPYD variant data with clinical characteristics greatly enhances the ability to identify patients at risk for extreme FP-related toxicity, emphasizing the importance of
Pharmacogenomic-guided dosing of fluoropyrimidines beyond : time for a polygenic algorithm?
Front Pharmacol
May 2023
Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs capecitabine (CAP) and tegafur. Bioconversion of 5-FU prodrugs to 5-FU and subsequent metabolic activation of 5-FU are required for the formation of fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate, the active nucleotides through which 5-FU exerts its antimetabolite actions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!